The ARROW® JACC is indicated for short to
long-term dwell. The catheter offers Vascular Access Specialists
another option when peripheral venous access is not an option.
LIMERICK, Pa.--(BUSINESS WIRE)--Sep. 19, 2013--
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical
devices for critical care and surgery, has announced the launch of the
new ARROW® JACC with Chlorag+ard®
Technology.
The ARROW® JACC (Jugular Axillo-subclavian Central Catheter)
with Chlorag+ard® Technology is a small-french
size antimicrobial and antithrombogenic catheter that is designed for
both acute and long-term use. The ARROW® JACC employs Chlorag+ard®
Technology as a weapon against thrombosis and infection for up to 30
days, effective against the full spectrum of bacterial and fungal
pathogens. Approximately 250,000 patients acquire catheter-related
bloodstream infections each year in the United States, with oncology,
diabetic, critically ill and chronically ill patients at highest risk.
According to the CDC, an estimated 30,000 to 62,000 patients die each
year as a result of a catheter-related bloodstream infection.1
The ARROW® JACC with Chlorag+ard®
Technology provides caregivers another tool to effectively and
economically care for millions of patients.
“We are very excited to announce our launch of the ARROW®
JACC with Chlorag+ard® Technology. This product’s
innovative design offers clinicians a new and unique treatment option
that further demonstrates our commitment to achieve ‘Zero Complications’
in vascular access,” said Benson Smith, Chairman, President, and Chief
Executive Officer. “We believe the ARROW® JACC represents a
significant step forward in raising the standard of care for patients
requiring vascular access, while equally addressing the clinical need
for treatment efficiency and cost-effectiveness in our challenging
healthcare environment.”
The ARROW® JACC, which received FDA clearance in November
2012, is designed specifically for the Vascular Access Specialist. The
placing of Central Venous Catheters by Vascular Access Specialists is an
emerging trend within healthcare. The Vascular Access Specialists are
driving best practices, such as the use of antimicrobial catheters,
ultrasound and maximal barrier precautions, to offset the high-demand
and workload of physicians who have traditionally placed central
catheters. To date, Teleflex Incorporated and its ARROW®
Vascular Division have supported clinicians in expanding their scope of
practice to include Central Venous Catheter insertion in more than forty
states.
To foster this growth, Teleflex has developed a comprehensive education
and training program focusing on the insertion of Central Venous
Catheters. This program is being licensed to institutions and academic
medical centers to help grow Vascular Access Teams and establish a high
standard of care.
“As an early user of the JACC since April, the power and versatility of
the device has become more evident the more that I use it. We have fully
integrated its use into our renal practice and are expanding its use in
other areas,” said Darla Tarvin, Vascular Access Specialist. “It’s the
right catheter for the patient and the kit is packaged in a way that
makes it the right catheter for me to insert. The ARROW® JACC
and kit has improved my ability to provide the best care possible to my
patients.”
* Not all products or technologies are approved for use in all
regulatory jurisdictions. Please contact your local Teleflex office or
representative for details.
Darla Tarvin is a paid consultant who performs speaking engagements on
behalf of Teleflex.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Limerick, PA,
Teleflex employs approximately 11,500 people worldwide and serves
healthcare providers in more than 140 countries. Additional information
about Teleflex can be obtained from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, Arrow and Chlorag+ard are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates.
© 2013 Teleflex Incorporated. All rights reserved. 2013-2357
References: 1. Grady NP AM, Dellinger EP, Heard SO, et al. Guidelines
for the Prevention of Intravascular Catheter- Related Infections:
Centers for Disease Control; 2002
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836